Endogenous Estrogens and Colorectal Cancer Risk in Women

女性内源性雌激素和结直肠癌风险

• 批准号: 7048599
• 负责人: Anne Zeleniuch-Jaquotte
• 金额: $ 18.57万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7048599
• 关键词: adenocarcinoma; androgens; biomarker; cancer risk; clinical research; colorectal neoplasms; estrogen receptors; estrogens; female; hormone regulation /control mechanism; hormone therapy; human subject; human therapy evaluation; longitudinal human study; neoplasm /cancer epidemiology; patient oriented research; postmenopause; questionnaires; serum globulins; women' s health

DESCRIPTION (provided by applicant): The evidence from epidemiologic studies that hormone replacement therapy is associated with a decreased risk of colorectal cancer (CRC) has been considerably strengthened by the recent observation of a statistically significant reduction in risk of CRC in the Women's Health Initiative, a large, randomized, placebo-controlled, clinical trial. Despite the evidence on the protective role of exogenous estrogens in CRC development, there are no epidemiologic studies to date on the association of endogenous estrogens with CRC risk. We propose to test the hypothesis that postmenopausal serum levels of estrogens and androgens are negatively associated with subsequent risk of CRC in a case-control study nested within the New York University Women's Health Study (NYUWHS) cohort. Between 1985 and 1991, the NYUWHS enrolled 14,275 healthy women who have been actively followed up ever since. Serum samples collected at time of enrollment were frozen for future biochemical analyses. A total of 227 cases of colorectal adenocarcinoma are expected to be diagnosed by March 2005 in participants who were postmenopausal at entry, and these cases will be included in the proposed study. For each case, two controls will be selected who match the case on age at, and date of, enrollment, and menopausal status at enrollment. Frozen serum samples from cases and matched controls will be retrieved and assayed for estradiol, estrone, estrone sulfate, androstenedione, testosterone, and SHBG. Data on potential confounders were collected previously. This study will be the first study on the association of postmenopausal circulating estrogen and androgen levels with CRC risk. The NYUWHS is particularly well suited to study the proposed hypothesis because of its prospective design which minimizes the risk for bias and allows to examine pre-diagnostic hormone levels, and because the role of endogenous sex hormones in the development of diseases has always been its primary focus.

描述（由申请人提供）：流行病学研究的证据表明激素替代疗法与结直肠癌（CRC）的降低相关，这是由于最近观察到妇女健康计划中CRC风险的统计显着降低，一项大型，随机的，随机的，安慰剂，安慰剂控制，临床试验的CRC风险降低。尽管有证据表明外源性雌激素在CRC发育中的保护作用，但迄今为止，尚无关于内源性雌激素与CRC风险的关联的流行病学研究。我们建议检验以下假设：在嵌套在纽约大学女子健康研究（NYUWHS）同胞中的病例对照研究中，雌激素和雄激素的绝经后血清水平与随后的CRC风险负相关。在1985年至1991年之间，NYUWH招募了14,275名健康妇女，这些妇女从那以后一直积极进行。在入学时收集的血清样品被冷冻以进行未来的生化分析。预计将在2005年3月在绝经后的参与者中诊断出227例结直肠腺癌病例，这些病例将包括在拟议的研究中。对于每种情况，将选择两个控制措施，以匹配年龄，注册日期，入学日期和更年期状态。将检索并测定来自病例和匹配对照的冷冻血清样品，并分析雌二醇，雌酮，硫酸雌酮，雄激素，睾丸激素和SHBG。先前收集了有关潜在混杂因素的数据。这项研究将是关于绝经后循环雌激素和雄激素水平与CRC风险的首次研究。 NYUWH特别适合研究拟议的假设，因为其前瞻性设计可最大程度地减少偏见的风险并允许检查诊断前激素水平，并且因为内源性性激素在疾病发展中的作用一直是其主要重点。